RESPONSE RATES TO SOFOSBUVIR AND DACLATASVIR IN CHRONIC HEPATITIS C PATIENTS
Article Sidebar
Main Article Content
Abstract
Objectives: To evaluate the effectiveness of daclatasvir and sofosbuvir in treating hepatitis C genotype 3a patients
Material and Methods This was a prospective interventional study .Consecutive non probability sampling technique
was followed . It was carried out in Department of Medicine KRL hospital Islamabad, Pakistan from February 2017 to
June 2018. This study included 80 patients who were infected with hepatitis C virus. Age ranged from 17-83 years.
Amongst them 70 were treatment naive while 10 has received Pegylated Interferon and ribavirin in the past. Of treatment
experienced 7 out of 10 patients had achieved SVR. Before starting treatment baseline laboratory tests were done
and recorded. Quantitative PCR for HCV RNA and Genotyping was done. All patients received treatment for 3 months.
Patients had a follow up every two weeks. Quantitative PCR for HCV RNA was performed at the end of treatment,3
months and 6 months after completion of treatment. Response rates were recorded. Data was analysed using statistical
package for social sciences version 17 (SPSS 17).
Results: Out of 80 patients54 (67%) were females and 26 (33%) were males. All patients were of genotype 3a. 70
patients (87%) had never experienced treatment before and 10 patients(13%) had previous treatment with pegylated
interferon and ribavirin. End of treatment response was observed in 98.8% of patients while sustained virological response(
SVR 12) and SVR 24 was observed in 96.25% of patients. Side effects mainly constitutional symptoms occured
in about one tenth of patients.
Conclusion: Directly acting antiviral drugs(DAA) have improved outlook in hepatitis C treatment while concomitantly
reducing the duration of treatment and has high safety profile.
Article Details
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.